-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $19

Benzinga·08/17/2026 12:26:21
Listen to the news
Canaccord Genuity analyst Caitlin Cronin maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $15 to $19.